Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK
Clin Ther. 2003 Jun;25(6):1700-21.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H
J Rheumatol. 2002 Nov;29(11):2288-98.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study
Heiberg MS, Rodevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, Kvien TK.
Ann Rheum Dis. 2006 Oct;65(10):1379-83. Epub 2006 May 5
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA
Ann Rheum Dis. 2006 Feb;65(2):257-60. Epub 2005 Jun 23
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab therapy: clinical findings and implications for integration into clinical guidelines for rheumatoid arthritis
Emery P
Drugs Today (Barc). 2005 Mar;41(3):155-63
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M
Arthritis Res Ther. 2005;7(2):R250-5. Epub 2005 Jan 10
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL.
Arthritis Res Ther. 2006;8(1):R3
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
Arthritis Rheum. 2004 May;50(5):1400-11.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.
Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N.
Rheumatology (Oxford). 2004 Jun;43(6):712-8. Epub 2004 Mar 23.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H
Ann Rheum Dis. 2004 May;63(5):508-16
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Role of adalimumab in the treatment of early rheumatoid arthritis.
Keystone EC, Haraoui B, Bykerk VP.
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S198-9.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H
Ann Rheum Dis. 2003 Dec;62(12):1168-77.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG
Ann Rheum Dis. 2006 Jun;65(6):753-9. Epub 2005 Nov 24
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK
Arthritis Rheum. 2003 Jan;48(1):35-45. Erratum in: Arthritis Rheum. 2003 Mar;48(3):855.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT
Arthritis Rheum. 2006 Jan;54(1):26-37
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK
J Rheumatol. 2003 Dec;30(12):2563-71
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab
Zikou AK, Argyropoulou MI, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, Drosos AA
J Rheumatol. 2006 Feb;33(2):219-23
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK
Arthritis Rheum. 2004 May;50(5):1400-11.

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.
den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P.
Ann Rheum Dis. 2002 Apr;61(4):311-8.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial
Kivitz A, Cohen S, Dowd JE, Edwards W, Thakker S, Wellborne FR, Renz CL, Segurado OG
Clin Ther. 2006 Oct;28(10):1619-29.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C
Ann Rheum Dis. 2006 Jul;65(7):889-94. Epub 2006 Jan 26
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG
Ann Rheum Dis. 2006 Jun;65(6):753-9. Epub 2005 Nov 24
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study
Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetsanopoulou AI, Georgiadis AN, Drosos AA
Ann Rheum Dis. 2006 Feb;65(2):257-60. Epub 2005 Jun 23
www.ncbi.nlm.nih.gov/entrez/query.fcgi

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT
Arthritis Rheum. 2006 Jan;54(1):26-37
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B
Rheumatology (Oxford). 2005 Aug;44(8):1026-31. Epub 2005 May 3.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H
Ann Rheum Dis. 2004 May;63(5):508-16
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
Patel T, Gordon KB.
Dermatol Ther. 2004;17(5):427-31. Review.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK
Clin Ther. 2003 Jun;25(6):1700-21.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK
J Rheumatol. 2003 Dec;30(12):2563-71
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Moutsopoulos HM, Beck K, Kupper H
Ann Rheum Dis. 2003 Dec;62(12):1168-77.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C
Ann Rheum Dis. 2006 Jul;65(7):889-94. Epub 2006 Jan 26
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure.
Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B
Rheumatology (Oxford). 2005 Aug;44(8):1026-31. Epub 2005 May 3.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab alone and in combination with disease- modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial.
Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, Bijlsma JW, Unnebrink K, Kary S, Kupper H
Ann Rheum Dis. 2007 Mar 20
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab
Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA.
Clin Exp Rheumatol. 2006 May-Jun;24(3):309-12
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
Capsoni F, Sarzi-Puttini P, Atzeni F, Minonzio F, Bonara P, Doria A, Carrabba M
Arthritis Res Ther. 2005;7(2):R250-5. Epub 2005 Jan 10
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis.
den Broeder AA, Wanten GJ, Oyen WJ, Naber T, van Riel PL, Barrera P
J Rheumatol. 2003 Feb;30(2):232-7.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab for treating rheumatoid arthritis
Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I
J Rheumatol. 2006 Jun;33(6):1075-81. Epub 2006 May 1
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab for treating rheumatoid arthritis
Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005113
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab in rheumatoid arthritis
Moreland L
Curr Rheumatol Rep. 2004 Oct;6(5):333-4
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab therapy in rheumatoid arthritis.
Keystone E, Haraoui B
Rheum Dis Clin North Am. 2004 May;30(2):349-64, vii. Review
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab: a review of its use in rheumatoid arthritis.
Bang LM, Keating GM
BioDrugs. 2004;18(2):121-39. Review
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
Patel T, Gordon KB.
Dermatol Ther. 2004;17(5):427-31. Review.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control.
Emery P
Drugs Today (Barc). 2003;39 Suppl B:17-23. Review.
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab (HUMIRA): a review.
Scheinfeld N
J Drugs Dermatol. 2003 Aug;2(4):375-7. Review
www.ncbi.nlm.nih.gov/entrez/query.fcgi

Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease.
Machold KP, Smolen JS.
Expert Opin Biol Ther. 2003 Apr;3(2):351-60. Review
www.ncbi.nlm.nih.gov/entrez/query.fcgi